Literature DB >> 30403943

A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

Yutaka Niihara1, Wally R Smith2, Charles W Stark3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30403943     DOI： 10.1056/NEJMc1811050

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

2.  To Give or Not to Give: RhD Immunoglobulin for an RHD *39 Pregnant Woman with Sickle Cell Disease.

Authors:  Justin E Juskewitch; Craig D Tauscher; Sheila K Moldenhauer; Jennifer E Schieber; Eapen K Jacob; Margaret A DiGuardo
Journal:  Transfus Med Hemother       Date:  2021-02-25       Impact factor: 3.747

3.  Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice.

Authors:  Nicole H Lopez; Biaoru Li; Chithra Palani; Umapathy Siddaramappa; Mayuko Takezaki; Hongyan Xu; Wenbo Zhi; Betty S Pace
Journal:  PLoS One       Date:  2022-05-31       Impact factor: 3.752

Review 4.  Pain in sickle cell disease: current and potential translational therapies.

Authors:  Varun Sagi; Aditya Mittal; Huy Tran; Kalpna Gupta
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

5.  Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.

Authors:  Belhu Metaferia; Troy Cellmer; Emily B Dunkelberger; Quan Li; Eric R Henry; James Hofrichter; Dwayne Staton; Matthew M Hsieh; Anna K Conrey; John F Tisdale; Arnab K Chatterjee; Swee Lay Thein; William A Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

Review 6.  Efficient Clinical Counseling for Sickle Cell Disease.

Authors:  Kerry A Morrone; Deepa Manwani; Michael D Cabana
Journal:  J Natl Med Assoc       Date:  2021-02-17       Impact factor: 2.739

Review 7.  Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.

Authors:  Françoise Bernaudin
Journal:  J Clin Med       Date:  2019-09-22       Impact factor: 4.241

8.  Pyridoxamine: another vitamin for sickle cell disease?

Authors:  Marilyn J Telen
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.